Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer
June 29th 2017Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Read More
Dr. Freedman on Preventing Brain Metastases in HER2+ Breast Cancer
June 20th 2017Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses preventing brain metastases in patients with HER2-positive breast cancer.
Read More
Dr. Freedman Discusses CNS Metastases in HER2+ Breast Cancer
June 15th 2017Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses brain metastases in patients with HER2-positive breast cancer.
Read More